Tscan Therapeutics is trading 5.3% down today at $0.80, extending its recent weakness amid broader sector-driven pressure and risk-off sentiment in biotech and growth stocks.
- The decline follows several consecutive down days for the stock, tracking a wider selloff across the biotechnology sector.
- There are no fresh, company-specific news or regulatory filings today; the move is attributed to macro trends rather than a new internal catalyst.